The 24th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2015). Istanbul, Turkey, March 12-15, 2015

Conference Reports for NATAP


The 24th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2015) Istanbul, Turkey, March 12-15, 2015

	Sofosbuvir Plus Ribavirin for the Treatment of Russian Patients With Chronic HCV Genotype 1 or 3 Infection - (04/01/15) Sofosbuvir Plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Egyptian Patients With Chronic Genotype 4 HCV Infection - (03/27/15) Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials - (03/27/15) Characterization of HBsAg Decline in the Tenofovir Disoproxil Fumarate and Peginterferon Alfa-2a Combination Study for Chronic Hepatitis B - (03/27/15) HBsAg Loss With Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a in Chronic Hepatitis B: Results of a Global Randomized Controlled Trial - (03/27/15) HBV DNA and Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate Following 8 Years of Therapy - (03/27/15) Impact of Tenofovir Disoproxil Fumarate on the Fasting Lipid Profile of Chronic Hepatitis B Patients - (03/27/15) No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment - (03/27/15) Efficacy, safety and pharmacokinetics of 12 weeks of simeprevir in combination with TMC647055 and ritonavir with or without ribavirin in genotype 1 hepatitis C virus-infected patients - (03/18/15) Simeprevir plus peginterferon/ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection: Results from the Phase III TIGER study conducted in East Asian patients living in China and Korea - (03/18/15) All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected with HCV Genotype 1b: The AI447031 Study - (03/18/15) All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15) Exposure-Efficacy Analysis for Daclatasvir and Asunaprevir in DUAL Combination in Non-Japanese and Japanese Subjects with Genotype 1b Hepatitis C Virus Infection - (03/18/15) Characterization of Resistance in HCV Genotype 1b-Infected Japanese and Western Patients Treated With an Interferon- and Ribavirin-Free Regimen of Ombitasvir and Paritaprevir/Ritonavir - (03/18/15) LONG-TERM EFFICACY AND SAFETY OF THE INTERFERON- AND RIBAVIRIN-FREE REGIMEN OF PARITAPREVIR/RITONAVIR AND OMBITASVIR IN HCV GENOTYPE 1B-INFECTED TREATMENT-EXPERIENCED JAPANESE PATIENTS - (03/18/15) Elderly and Cirrhotic Patients Without Baseline NS5A Polymorphisms in HCV Genotype 1b Have Very High Sustained Virologic Responses to Daclatasvir Plus Asunaprevir - (03/18/15)